Moleculin Biotech, Inc. 8-K

What Happened Moleculin Biotech, Inc. (MBRX) filed a Form 8-K on June 30, 2026 disclosing a press release that announced positive preliminary unblinded efficacy results from the first 45 patients enrolled in Part A of its pivotal Phase 2/3 MIRACLE trial. The analysis was performed on a full intent-to-treat basis with no patient exclusions. Both Annamycin treatment arms showed favorable efficacy trends compared with the control arm in patients with relapsed or refractory acute myeloid leukemia (R/R AML).

Key Details

• The update covers the first 45 patients in Part A of the MIRACLE trial (analyzed on a full intent-to-treat basis).
• Both Annamycin treatment arms trended favorably versus the control arm in R/R AML (exact efficacy measures were described in the attached press release).
• The disclosure was made via press release attached to the 8-K as Exhibit 99.1, filed June 30, 2026.
• The 8-K was a Regulation FD disclosure (public release of material clinical-trial information).

Why It Matters This is an early, company-reported clinical result for a pivotal Phase 2/3 study of Annamycin in R/R AML — a key program for Moleculin. Positive preliminary trends can influence investor interest and future clinical and regulatory milestones, but the results are preliminary and were reported as trends rather than final, peer-reviewed or fully quantified outcomes. Investors should watch for full trial data, confirmatory analyses, and subsequent regulatory updates.